Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01166490 | A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma | PHASE1 | COMPLETED | 51 | — | — | Jul 1, 2010 | Jul 1, 2013 | Aug 27, 2013 | 7 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | ASG-5ME |
| Name | Type | Description |
|---|---|---|
| ASG-5ME | DRUG | 0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles |
Inclusion Criteria: * Pathologically confirmed metastatic pancreatic adenocarcinoma or pathologically confirmed AGS-5-positive gastric or gastric esophageal junction adenocarcinoma * Measurable disease (at least one nonresectable, non-nodal lesion greater than or equal to 10 mm in longest diameter ...